Jonathan Milner releases presentation to Abcam plc shareholders, outlining reasons to reject Danaher's bid and strategic vision for the Company
- Jonathan Milner releases presentation to Abcam plc shareholders, outlining reasons to reject Danaher's bid and strategic vision for the Company
- 10/16/2023
|
Exlusive: Why Abcam founder believes Danaher's acquisition offer falls short
- In an exclusive interview with Thomas Warner (TW) of Proactive London, Dr Jonathan Milner (JM), the founder of life sciences company Abcam PLC (NASDAQ:ABCM), discusses why he believes the $24 per share acquisition offer from Danaher (NYSE:DHR) severely undervalues the company. Milner criticises the timing of the deal and advises shareholders to consider whether the $5.7 billion acquisition is in their best interest.
- 10/16/2023
|
ABCAM INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Abcam plc - ABCM
- NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Abcam plc (NasdaqGS: ABCM) to Danaher Corporation (NYSE: DHR). Under the terms of the proposed transaction, shareholders of Abcam will receive $24.00 in cash for each share of Abcam that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the.
- 10/10/2023
|
Jonathan Milner issues Open Letter to shareholders of Abcam plc
- Urges shareholders to question the scheme circular, the unacceptable Offer price and continue to Vote AGAINST the current proposed acquisition of Abcam by Danaher Corporation
- 10/10/2023
|
GMED or ABCM: Which Is the Better Value Stock Right Now?
- Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or Abcam PLC Sponsored ADR (ABCM). But which of these two stocks offers value investors a better bang for their buck right now?
- 10/05/2023
|
Jonathan Milner issues Open Letter to shareholders of Abcam plc
- Jonathan Milner issues Open Letter to shareholders of Abcam plc U rges shareholders to Vote AGAINST the proposed acquisition of Abcam by Danaher Corporation CAMBRIDGE, England, 2 8 September 2023 – Dr. Jonathan Milner, the founder and one of the largestinvestors in Abcam plc (“Abcam” or the “Company”) (NYSE: ABCM) with ownership of 6.15%, todayissued an open letter to the Company's shareholders announcing his “Vote AGAINST” campaign and providing them with the opportunity to send a clear message to the Board that they are dissatisfied with the proposed acquisition of Abcam by Danaher Corporation (NYSE: DHR) or its affiliates (“Danaher”) and Abcam's governance, execution and cost control. Find out more and read the full text of the letter at the Focus Abcam website.
- 09/28/2023
|
Abcam plc Statement on Dr. Jonathan Milner's Announcement
- CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Abcam plc (Nasdaq: ABCM) (“Abcam” or the “Company”), notes today's announcement by Dr. Jonathan Milner. The Company considers it surprising that Dr. Milner has taken active steps to oppose the deal without reviewing the full details in the Scheme Circular to be published in connection with the proposed acquisition of all of the outstanding shares of Abcam by Danaher Corporation (“Danaher”) for $24.00 per share in cash (the “Transaction”), wh.
- 09/14/2023
|
Dr. Jonathan Milner opposes Danaher's acquisition of Abcam and calls for EGM to replace Board
- Dr. Jonathan Milner opposes Danaher's acquisition of Abcam and calls for EGM to r eplace Board
- 09/14/2023
|
Abcam plc Interim Results for the Six-Month Period Ended 30 June 2023
- CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Abcam plc (Nasdaq: ABCM) (‘Abcam', the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, today announces its interim results for the six-month period ended 30 June 2023 (the ‘period'). FINANCIAL PERFORMANCE Six months ended £m, unless stated otherwise 30 June 2023 30 June 2022 Revenue 203.2 185.2 Reported gross profit margin, % 76.2% 74.1% Adjusted gross profit margin*, % 76.2% 75.6% Reported.
- 08/31/2023
|
ABCAM INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Abcam plc - ABCM
- NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Abcam plc (NasdaqGS: ABCM) to Danaher Corporation (NYSE: DHR). Under the terms of the proposed transaction, shareholders of Abcam will receive $24.00 in cash for each share of Abcam that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the.
- 08/29/2023
|
Danaher Buys Abcam for $5.7 Billion to Expand Its Product Offerings
- Medical tool supplier Danaher (DHR) is expanding its product offerings by purchasing British biotech firm Abcam Plc (ABCM) for $5.7 billion, including debt.
- 08/28/2023
|
ABCM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Abcam plc Is Fair to Shareholders
- NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Abcam plc (NASDAQ: ABCM) to Danaher Corporation for $24.00 per share in cash is fair to Abcam shareholders. Halper Sadeh encourages Abcam shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Abcam and its board of d.
- 08/28/2023
|
Danaher acquires biotech supplier Abcam for $5.7B
- Danaher (NYSE:DHR) said it will be acquiring UK-based biotechnology supplier Abcam (AIM:ABC) for $24 per share or a total enterprise value of about $5.7 billion. Danaher (NYSE:DHR) beat out rivals who were also bidding for the company including Agilent Technologies (NYSE:A), according to media reports.
- 08/28/2023
|
Medical tech firm Danaher to buy Abcam in deal valued at $5.7 bln
- Danaher Corp said on Monday it would buy smaller rival Abcam Plc in a deal valued at $5.7 billion including debt, as the medical tools supplier eyes bigger contracts by expanding its services.
- 08/28/2023
|
Danaher to Buy Abcam in $5.7 Billion Deal. Investors Don't Like the Premium.
- The industrial scientific-supplies company agrees to acquire all shares outstanding for $24.00 each.
- 08/28/2023
|
Abcam agrees to be acquired by Danaher in $5.7B deal
- Abcam Plc stock ABCM, +3.87% was up 0.4% in premarket trades Monday after it said it agreed to be acquired by Danaher Corp. DHR, +0.78% for $24 a share in cash in a deal that values the maker of antibodies and reagents for drug discovery efforts at about $5.7 billion including debt. The price amounts to a premium of 64 cents a share, or 2.7% over its closing price of $23.36 on Friday.
- 08/28/2023
|
Exclusive: Danaher in the lead to acquire biomedical equipment vendor Abcam-sources
- Danaher Corp is in the lead to acquire Abcam Plc , a provider of supplies to life science researchers with a market value of $5.1 billion, as it expands its biomedical offerings, people familiar with the matter said on Friday.
- 08/25/2023
|
Why Shares of Abcam Are Jumping Friday
- Abcam specializes in products, such as assays or reagents, used in biologic drug discovery. The company saw revenue grow but reported a loss in 2022.
- 06/23/2023
|
Are You Looking for a Top Momentum Pick? Why Abcam PLC Sponsored ADR (ABCM) is a Great Choice
- Does Abcam PLC Sponsored ADR (ABCM) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 06/21/2023
|
3 Stocks With Upgraded Broker Ratings for Robust Returns
- As brokers have a deeper insight into stocks, one must follow rating upgrades for solid returns. We choose Abcam (ABCM), Maxeon Solar (MAXN) and Allegiant Travel (ALGT) as these witness rating upgrades.
- 06/21/2023
|
Is Abcam (ABCM) Outperforming Other Medical Stocks This Year?
- Here is how Abcam PLC Sponsored ADR (ABCM) and Apyx Medical (APYX) have performed compared to their sector so far this year.
- 06/20/2023
|
Why Shares in Abcam Surged This Week
- Abcam operates in some highly attractive end markets, but its operational execution is not what it should be, according to its funder and former director. Dr. Jonathan Milner has called for the removal of three board members and his appointment as executive chairman.
- 06/15/2023
|
Abcam: Nosebleed Valuations, Flat Growth Profile Justify Hold Rating
- Abcam plc's outlook remains unchanged after a mixed FY'22, with improvements needed in fundamental, sentiment, and valuation factors to attract buyers. Despite a strong FY'22, ABCM's poor returns on capital, economic losses and flat growth outlook hinder its investment potential. The company needs to enhance performance across key metrics to create value for shareholders and warrant a buy rating.
- 06/09/2023
|
How Much Upside is Left in Abcam PLC Sponsored ADR (ABCM)? Wall Street Analysts Think 27.55%
- The mean of analysts' price targets for Abcam PLC Sponsored ADR (ABCM) points to a 27.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 05/23/2023
|
Abcam plc (ABCM) Q4 2022 Earnings Call Transcript
- State Bank of India ADR (NASDAQ:ABCM ) Q4 2022 Earnings Conference Call March 20, 2023 8:00 AM ET Company Participants Tommy Thomas - Vice President of Investor Relations Alan Hirzel - Chief Executive Officer Michael Baldock - Chief Financial Officer Conference Call Participants Tejas Sevant - Morgan Stanley Puneet Souda - SBV Securities Matt Larew - William Blair Michael Ryskin - Bank of America Charles Weston - RBC Justin Bowers - Deutsche Bank Operator Hello, and welcome to the Abcam plc Full-Year 2022 Earnings Conference Call. My name is Alex, I'll be coordinating the call today.
- 03/20/2023
|
Abcam to Report Full Year Results on Monday, March 20, 2023
- CAMBRIDGE, England and WALTHAM, Mass. , March 10, 2023 /PRNewswire/ -- Abcam plc (Nasdaq: ABCM) ("Abcam" or the "Company"), a global leader in the supply of life science research tools, will report its results for the year ended 31 December 2022 at 7.00 a.m.
- 03/10/2023
|
Abcam: A Good Growth Stock In The Healthcare Market
- I will update my previously published article on Abcam from 15 months ago. Readers will have the opportunity to learn about interim events with the company.
- 09/29/2022
|
Abcam plc (ABCM) Q4 2022 Earnings Call Transcript
- Abcam plc (NASDAQ:ABCM ) Q4 2022 Results Conference Call September 12, 2022 8:00 AM ET Company Participants Tommy Thomas - IR Alan Hirzel - CEO Michael Baldock - CFO Conference Call Participants Tejas Savant - Morgan Stanley Charles Weston - RBC Puneet Souda - SBV Securities Matt Larew - William Blair Michael Ryskin - Bank of America. Operator Ladies and gentlemen, welcome to the Abcam Interim Results Webcast for the period ending June 30, 2022.
- 09/12/2022
|
Abcam (ABCM) CEO, Alan Hirzel on Q4 2021 Results - Earnings Call Transcript
- Abcam (ABCM) CEO, Alan Hirzel on Q4 2021 Results - Earnings Call Transcript
- 03/14/2022
|
4 High Financial Strength Stocks Trading Near Historical Low Price-Book Ratios
- According to the Historical Low Price-Book Screen, a Premium feature of GuruFocus, four stocks with high financial strength and are trading near historical low price-book ratios are Landstar System Inc. ( LSTR , Financial), 51job Inc. ( JOBS , Financial), Abcam PLC ( ABCM , Financial) and SAP SE ( SAP , Financial).
- 09/15/2021
|
Abcam jumps as it snaps up major supplier BioVision
- Abcam PLC shares rose on Monday as the research tools maker said it had struck a deal to acquire BioVision Inc, a subsidiary of chemicals firm Chinese firm NKY Medical Holdings, for US$340mln in cash. BioVision distributes research tools and has a strength in the assay kits market, Abcam said, adding that the purchase will bring one of its large third-party suppliers in-house.
- 08/02/2021
|
Abcam To Acquire Supplier BioVision For $340M In Cash
- Abcam plc (NASDAQ: ABCM) has agreed to acquire BioVision Inc, a wholly-owned Boai NKY Medical Holdings Ltd subsidiary, for $340 million in cash. The Milpitas, California-based BioVision is a distributor of life science research tools to biopharma, diagnostic and academic customers, with strength in biochemical and cell-based assay kits.
- 08/02/2021
|
Abcam to Acquire BioVision for $340 million
- CAMBRIDGE, United Kingdom, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Abcam plc (AIM LSE: ABC; Nasdaq: ABCM) ("Abcam", “the Company” or "the Group"), a global leader in the supply of life science research tools, today announces that it has entered into a definitive agreement to acquire BioVision, Inc. ("BioVision"), a wholly owned subsidiary of Boai NKY Medical Holdings Ltd. (“NKY”), for $340 million (the “Acquisition”).
- 08/02/2021
|
New Strong Sell Stocks for July 29th
- ABCM, CCJ, EBMT, MRTN and NESR have been added to the Zacks Rank #5 (Strong Sell) List on July 29, 2021.
- 07/29/2021
|
Proteomics International engages Abcam to manufacture PromarkerD reagents
- Proteomics International Laboratories Ltd (ASX:PIQ) has engaged global life science company Abcam plc (LON:ABC) (OTCMKTS:ABCZF) to manufacture reagents for the immunoassay version of its PromarkerD predictive blood test for the early detection of kidney disease in patients with type 2 diabetes. Abcam is a leader in the supply of life science research tools and reagents, including supply to those companies developing and marketing diagnostic solutions around the world.
- 07/22/2021
|
Abcam opens new US facility in Boston, MA
- CAMBRIDGE, July 13, 2021 /PRNewswire/ -- Abcam (AIM: ABC) (NASDAQ: ABCM), a global innovator in life sciences reagents and tools, today announces the opening of a major new site in Waltham, MA. The new facility is a central component of Abcam's growth in the United States, reinforcing its commitment to support the research and biopharma sector globally and serving as a hub for the Company's R&D and commercial activities in the region.
- 07/13/2021
|
Abcam: A Promising Business Model In The Drug Industry
- I will outline the history of drug development. Information for the Abcam business model will be outlined for my readers.
- 07/09/2021
|
Pionyr and Abcam extend partnership to evaluate TREM2-expressing cells in cancer patients
- SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, England, June 22, 2021 /PRNewswire/ -- Today Pionyr Immunotherapeutics, Inc., a company developing first-in-class antibody therapeutics that increase the body's anti-tumor immunity and Abcam (AIM: ABC) (NASDAQ: ABCM), a global innovator in life science reagents and tools, announced the extension of their collaboration with a new commercial licensing agreement to support the progression of PY314, the first to the clinic of Pionyr's compounds.
- 06/22/2021
|
Abcam and MEDx extend precision medicine strategic partnership
- CAMBRIDGE, United Kingdom and SHANGHAI, China, April 12, 2021 (GLOBE NEWSWIRE) -- Abcam (AIM: ABC; NASDAQ: ABCM), a global innovator in life science reagents and tools, and MEDx Translational Medicine (MEDx), formerly QIAGEN (Suzhou) Translational Medicine Co., Ltd., a company dedicated to developing companion diagnostics and precision medicine, announced the extension of their strategic partnership to include the co-development and commercialization of key companion and in vitro diagnostic kits for MEDx to supply to the Chinese market.
- 04/12/2021
|
Avacta Announces Distribution Agreement With ABCAM plc
- CAMBRIDGE, England--(BUSINESS WIRE)--Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that it has entered into a global distribution agreement with ABCAM plc (AIM: ABC; NASDAQ: ABCM) to sell the Group's recently developed SARS-CoV-2 research ELISA Affimer® reagents. Avacta has developed Affimer® reagents which can be used in a high performance ELISA laboratory test to de
- 04/06/2021
|
5 Companies Trading Below Historical Low Price-Book as of March
- Stocks with high business profitability and price-book ratios near 10-year lows
- 03/26/2021
|
Abcam Wins Industry Awards from CiteAb
- CAMBRIDGE, United Kingdom, March 24, 2021 (GLOBE NEWSWIRE) -- Today Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life science reagents and tools, announced that Dr Alejandra Solache, SVP of Research & Development received the CiteAb award for ‘Significant Individual Impact' and the Company was recognized as ‘Antibody Supplier Succeeding in Cardiovascular Research'.
- 03/24/2021
|
Abcam (ABCZF) CEO, Alan Hirzel on 2021 Interim Results - Earnings Call Transcript
- Abcam (ABCZF) CEO, Alan Hirzel on 2021 Interim Results - Earnings Call Transcript
- 03/08/2021
|
8.3% constant currency revenue growth in H1 as customers gradually return to labs
- CAMBRIDGE, United Kingdom, March 08, 2021 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; AIM: ABC) (“Abcam”, the “Group” or the “Company”), a global leader in the supply of life science research tools, today announces its interim results for the six month period ended 31 December 2020 (“H1 2021”).
- 03/08/2021
|
Abcam Expands Presence in China to Support Increased Demand of BioPharma Sector
- CAMBRIDGE, United Kingdom, March 04, 2021 (GLOBE NEWSWIRE) -- Today Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life science reagents and tools, announced the expansion of its footprint in China with the opening of new custom-built facilities in Hangzhou and Shanghai. Expanded customer service, logistics and manufacturing capabilities are strengthening Abcam's position as a leading collaborator for academia and industry in the region.
- 03/04/2021
|
Abcam to Report Interim Results on Monday, March 8, 2021
- CAMBRIDGE, United Kingdom, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC; Nasdaq: ABCM) (“Abcam” or the “Company”), a global leader in the supply of life science research tools, will report its Interim Results for the six-month period ended 31 December 2020 at 12.00 p.m. GMT (7.00 a.m. EST) on Monday, March 8, 2021.
- 02/26/2021
|
Abcam to present at the 2021 SVB Leerink Global Healthcare Conference
- CAMBRIDGE, United Kingdom, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; LSE: ABC) today announced that Alan Hirzel, Chief Executive Officer, will present at the 2021 SVB Leerink Global Healthcare Conference on Friday, February 26, 2021 at 8.00 EST / 13.00 GMT. A live webcast of the presentation can be accessed via the IR Calendar page of Abcam's Investor Relations website at https://www.abcamplc.com/reports-presentations.
- 02/17/2021
|
Abcam Plc Appointment of Non-Executive Directors
- CAMBRIDGE, United Kingdom, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC; Nasdaq: ABCM) (“Abcam”), a global leader in the supply of life science research tools, is delighted to announce the appointments of Bessie Lee and Mark Capone as non-executive Directors with immediate effect.
- 01/28/2021
|
Abcam: An Attractive, Profitable Medtech But Pricy
- Abcam has a strong position in the niche of supplies for antibody research. It is profitable, dividend paying, and continues to grow well.
- 01/18/2021
|
